Multiplex IHC Assay for PD-L1 Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and differentiating PD-L1 positive tumor cells and immune cells in tissue samples are limited by variability in detection antibodies, tissue preparation, and reliance on morphological differences, which can lead to subjective scoring and reduced accuracy in predicting responses to PD-L1 targeted therapies.
Innovation Solution
A multiplex assay and kit system that uses a first primary antibody specific for PD-L1 and a second primary antibody specific for an immune cell marker, with detection reagents that deposit different dyes, allowing for the simultaneous identification and differentiation of PD-L1 positive and negative tumor and immune cells, and the quantification of tumor-infiltrating lymphocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunohistochemistry is used to measure PD-L1 expression, then PD-L1 status can be determined, but accuracy is reduced due to variable detection antibodies and tissue preparation
Solution Approach 1:
The patent combines multiple detection antibodies (anti-PD-L1 and anti-immune cell marker antibodies) into a single multiplex IHC assay. This merging of detection targets into one unified staining process eliminates variability between separate IHC procedures and allows simultaneous identification of PD-L1 positive tumor cells and immune cells with consistent results.
Solution Approach 2:
The multiplex IHC assay performs multiple functions simultaneously: it detects PD-L1 expression on tumor cells, identifies immune cells through their markers, and distinguishes between tumor and immune cells all in one staining procedure. This multi-functionality resolves the contradiction by providing both accurate PD-L1 measurement and reliable cell differentiation without requiring multiple separate assays.
2Ease of operation
If morphological differences are used to differentiate tumor and immune cells, then cell identification is possible, but subjectivity in scoring increases
Solution Approach 1:
The patent uses distinct chromogenic dyes (e.g., brown DAB for PD-L1 positive cells, blue for immune cells) to visually differentiate between tumor cells and immune cells. This color-based differentiation eliminates subjectivity in cell identification, as pathologists can objectively distinguish cell types based on stain color rather than relying on subtle morphological features that require subjective interpretation.
3Measurement precision
If separate staining procedures are used for PD-L1 and immune cell markers, then specific detection is achieved, but time and productivity are reduced
Solution Approach 1:
The patent merges the detection of multiple markers (PD-L1 and immune cell markers) into a single multiplex staining procedure. By combining what would traditionally require separate IHC assays into one unified process, the invention maintains specific marker detection while dramatically improving productivity and reducing the time required for analysis.
Solution Approach 2:
The multiplex IHC assay allows continuous detection of multiple targets in sequence within a single tissue section without requiring intermediate processing steps between stains. This continuous action eliminates the time loss associated with performing separate staining procedures and enables efficient high-throughput analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the accuracy and efficiency of identifying PD-L1 positive immune cells, reduces subjectivity in scoring, and improves the prediction of responses to PD-L1 targeted therapies by clearly distinguishing between PD-L1 positive tumor cells and immune cells on a single tissue sample.
Implementation Method 1
PD-L1 expression is measured most commonly by immunohistochemistry (IHC)
Implementation Method 2
contacting a tissue sample with a first detection reagent specific to PD-L1 and at least a second detection reagent specific to an immune cell marker
Data Source
AI summary
The present disclosure is directed to multiplex assays, kits and methods, including automated methods, for identifying PD-L1 positive immune cells, PD-L1 positive tumor cells, and PD-L1 negative immune cells within a tissue sample using two dyes selected from diaminobenzidine (DAB), 4-(dimethylamino) azobenzene-4′-sulfonamide (DABSYL), tetramethylrhodamine (DISCOVERY Purple), N,N′-biscarboxypentyl-5,5′-disulfonato-indo-dicarbocyanine (Cy5), and Rhodamine 110 (Rhodamine).